GATEWAY 2026
Threehorizons.
One company,
three doors.
Your bridge between the world and Japan's pharmaceutical & health industry.
8+
COUNTRIES
10+
PARTNERS
2023
FOUNDED
3
DOORS
From Japan, with partners in 8 countries.
- Bangladesh
- India
- Indonesia
- Italy
- Singapore
- Thailand
- and others
Countries where our contracted partners are based (partner names withheld).
Care Link
Specialty Pharma × Last Mile
Delivering directly to patients
Last-mile delivery of specialty pharmaceuticals from pharmacies to patient homes. End-to-end cold chain management, adherence monitoring, and PSP integration.
Global Bridge
Import × Export
A two-way bridge between Japan and the world
Japan market entry for overseas pharma and raw materials. Global expansion for Japanese OTC and supplements. Regulatory to logistics, end-to-end.
garden
Supplement Development
From idea to product
Supplement and health food planning to manufacturing. OEM/ODM, raw material sourcing, and branding support.
Latest Insights
Healthcare insights shared by CEO Masaya Yamamoto on NewsPicks
コーヒー3杯と認知症リスク―大規模コホート研究の可能性と限界
A large-scale cohort study tracking approximately 130,000 participants for up to 43 years deserves attention from an evidence-quality standpoint. The finding that consuming around three cups of coffee per day is associated with a reduced risk of dementia aligns with the direction of multiple previous observational studies, and I regard it as carrying a certain degree of credibility. That said, careful interpretation is essential. Because this remains an observational study, the association observed between coffee intake and dementia risk does not establish causation. Confounding factors—such as the tendency of health-conscious individuals to drink coffee in moderation—cannot be fully eliminated no matter how rigorously adjustments are made. While basic research does suggest neuroprotective effects from caffeine and chlorogenic acid found in coffee, extrapolating those findings to humans still warrants caution. Given coffee's potential impact on sleep and cardiovascular load, it would be premature to translate these results into a simple behavioral recommendation to 'drink coffee to prevent dementia.' From a public health perspective, what matters is situating coffee consumption within the broader context of one's overall lifestyle.
GLP-1薬とNAIONリスク ― FDA警告の証拠水準と臨床対応
Safety concerns surrounding GLP-1 receptor agonists have long included discussions of pancreatitis and thyroid cancer risk; the latest FDA warning adds non-arteritic anterior ischemic optic neuropathy (NAION)—a condition in which impaired blood flow to the optic nerve can cause vision loss. The evidence, however, warrants careful interpretation: the FDA itself states that the data are "insufficient to establish a causal relationship," and the signal comes from observational studies alone. Because patients prescribed GLP-1 therapies often carry background conditions such as diabetic vascular disease and hypertension—independent risk factors for NAION—confounding has not been ruled out. For clinicians, the appropriate response is not to curtail prescribing reflexively, but to conduct thorough ophthalmic risk assessments and careful follow-up for vulnerable patients. Given the well-established efficacy of this drug class for obesity and type 2 diabetes, an individualized benefit-risk appraisal remains essential. As indications for these agents expand in Japan, building reliable mechanisms for physicians and patients to share this information appropriately will be increasingly important.
若年脳卒中の増加 ― 医療の枠組みと予防体制の再設計
Reports of rising stroke rates among younger adults challenge the long-standing assumption that cardiovascular disease is primarily a problem of old age. Risk factors such as obesity, hypertension, and type 2 diabetes have been spreading to younger generations for some time, and we are now seeing that trend manifest as measurable increases in incidence. Crucially, this is not a uniquely American phenomenon. Westernized diets, declining physical activity, and chronic stress and sleep deprivation represent structural shifts shared across many developed nations—Japan included. Epidemiological data on stroke in younger Japanese adults remains insufficient, and it is entirely possible that a similar pattern is hiding in plain sight. The consequences of stroke in younger people are far-reaching in ways that differ from those in the elderly: the long-term impact on employment and caregiving capacity translates into substantial losses in quality of life and social productivity. From a prevention standpoint, this calls for lowering the effective age threshold for health screenings and guidance programs, and for embedding early risk stratification into routine clinical care. The 'younging' of disease demands that the mindset of healthcare providers evolve to keep pace.